Footnotes
ID | footnote |
f1 |
on november 16, 2020, mylan n.v. ("mylan") completed the transaction pursuant to which mylan combined with pfizer inc.'s ("pfizer") upjohn business (the "upjohn business") in a reverse morris trust transaction (the "combination") and upjohn inc. ("upjohn") became the parent entity of the combined upjohn business and mylan business and was renamed "viatris inc." ("viatris"). pursuant to the terms of the business combination agreement (as amended), dated july 29, 2019, by and among mylan, pfizer, upjohn and certain other affiliated entities, upjohn and mylan effected the combination through a series of transactions, including that (1) mylan merged with and into mylan ii b.v. with mylan ii b.v. surviving the merger as the legal successor of mylan and (2) each holder of mylan ordinary shares received one share of viatris common stock for each mylan ordinary share held by such holder (subject to any required withholding tax). |
f2 |
represents ordinary shares of mylan that were exchanged on a one-for-one basis for shares of viatris common stock in connection with the combination. on the effective date of the combination, the closing price of a mylan ordinary share was $15.85 per share. |
f3 |
each restricted stock unit ("rsu") represents the right to receive one ordinary share of mylan. the rsus vested in full on november 16, 2020 in connection with the conclusion of mr. vollebregt's service as a director on such date. |
f4 |
represents stock options to acquire mylan ordinary shares that were exchanged for stock options to acquire viatris common stock having substantially the same terms in connection with the combination. |
f5 |
these options vested on march 3, 2018. |
f6 |
these options vested on march 2, 2019. |
f7 |
these options vested on march 2, 2020. |
f8 |
these options vested in full on november 16, 2020 in connection with the conclusion of mr. vollebregt's service as a director on such date. |